Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Summary

This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.

Timeline

Start

2015-06

Primary completion

2016-02

Completion

2016-02

Outcome

Missed primary endpoint

registry analysis (other test); KQ-791 Dose 1 vs Placebo; Least-squares Mean Difference -6.78 (95% CI -23.75 to 10.18) NCT02445911 ↗

registry analysis (other test); KQ-791 Dose 2 vs Placebo; Least-squares Mean Difference -2.97 (95% CI -19.65 to 13.72) NCT02445911 ↗

registry analysis (other test); KQ-791 Dose 3 vs Placebo; Least-squares Mean Difference -5.05 (95% CI -21.97 to 11.88) NCT02445911 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KQ-791	Unknown	—	Oral

Indications